← FDA DRUG APPROVALS

FDA ANDA · ANDA075520

NORTRIPTYLINE HYDROCHLORIDE

Sponsor: TARO

APPLICATION
ANDA075520
TYPE
ANDA
ORIGINAL APPROVAL
2000-05-08
LATEST ACTION
2020-04-16
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

NORTRIPTYLINE HYDROCHLORIDEPrescription
NORTRIPTYLINE HYDROCHLORIDE EQ 25MG BASE · CAPSULE · ORAL
NORTRIPTYLINE HYDROCHLORIDEPrescription
NORTRIPTYLINE HYDROCHLORIDE EQ 50MG BASE · CAPSULE · ORAL
NORTRIPTYLINE HYDROCHLORIDEPrescription
NORTRIPTYLINE HYDROCHLORIDE EQ 10MG BASE · CAPSULE · ORAL
NORTRIPTYLINE HYDROCHLORIDEPrescription
NORTRIPTYLINE HYDROCHLORIDE EQ 75MG BASE · CAPSULE · ORAL

Approval history

2020-04-16Labeling · Supplement 8 · standardAP
2015-04-13Labeling · Supplement 6 · standardAP
2015-04-13Labeling · Supplement 4 · standardAP
2009-02-19Labeling · Supplement 3AP
2007-08-03Labeling · Supplement 2AP
2005-07-20Labeling · Supplement 1AP
2000-05-08OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →